EGFR and colorectal cancer: When the SW620 cells, which are colorectal cancer cells derived from the same patient as the SW480 but lack EGFR expression, were treated with EGFP-encapsulated R-MrNV and E-MrNV VLPs, the significantly lower percentages of EGFP positive cells in both chimeric VLPs (p < 0.01) were noted when compared to the percentages of EGFP-positive SW480 cells (Fig. 6) This suggested the lack of EGFR-specific enhancement of cargo delivery in these cells, as expected for EGFR-negative cells.